Filing Flows › Aurinia Pharmaceuticals (AUPH) › Q3 2026 › vs Q2 2026
Aurinia Pharmaceuticals (AUPH) Q3 2026 vs Q2 2026 (quarter over quarter)
Aurinia Pharmaceuticals's revenue rose $479K (+0.6%) from $83.2M in Q2 2026 to $83.7M in Q3 2026. The biggest changes: License, collaboration and royalty revenue +$473K (+12%); Net product sales +$6K (0%). Operating margin 42.3% against 55.7% (-13.4 pts).
Aurinia Pharmaceuticals, Q3 2026: revenue $83.7M (+14% year over year), operating margin 42.3%, net earnings $31.7M, operating cash flow $46.4M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 42.3% | 55.7% | -13.4 pts |
| Net margin | 37.9% | 45.0% | -7.1 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Net product sales | $79.4M | $79.4M | $6K | 0% |
| License, collaboration and royalty revenue | $4.3M | $3.8M | $473K | +12% |
| Revenue | $83.7M | $83.2M | $479K | +0.6% |
| Other income, net | $3.4M | $2.4M | $907K | +37% |
| Operating profit | $35.4M | $46.3M | −$11.0M | -24% |
| Costs & expenses | $48.3M | $36.9M | $11.5M | +31% |
| Pre-tax earnings | $38.7M | $48.8M | −$10.1M | -21% |
| Net earnings | $31.7M | $37.4M | −$5.7M | -15% |
| Income tax | $7.0M | $11.4M | −$4.4M | -38% |
| Depreciation & amortization | $4.8M | $4.8M | $7K | +0.1% |
| Share-based compensation | $6.1M | $2.8M | $3.3M | +116% |
| Working capital & other | $3.7M | $7.5M | −$3.8M | -51% |
| Operating cash flow | $46.4M | $52.6M | −$6.2M | -12% |
Questions
How much did Aurinia Pharmaceuticals's revenue grow quarter over quarter in Q3 2026?
Aurinia Pharmaceuticals's revenue rose $479K (+0.6%) from $83.2M in Q2 2026 to $83.7M in Q3 2026.
What drove Aurinia Pharmaceuticals's revenue change in Q3 2026?
License, collaboration and royalty revenue +$473K (+12%); Net product sales +$6K (0%).